LFCR

SEC source: 0001628280-24-044118 · wk-form4_1730234796.xml · nonDerivative · entry 1

Lake Ryan David · CIK 0001450325 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 337,500

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · shares: The performance-based restricted stock units vested based on the Issuer's achievement of a stock price milestone.

F2 · price: The performance-based restricted stock units convert into common stock of Lifecore Biomedical, Inc. on a 1 for 1 basis.

SEC source: 0001104659-24-106795 · tm2425764-1_4seq1.xml · nonDerivative · entry 2

WYNNEFIELD PARTNERS SMALL CAP VALUE LP I · CIK 0001251565 · 10% owner

WYNNEFIELD PARTNERS SMALL CAP VALUE LP · CIK 0000899083 · 10% owner

WYNNEFIELD SMALL CAP VALUE OFFSHORE FUND LTD · CIK 0001030806 · 10% owner

WYNNEFIELD CAPITAL MANAGEMENT LLC · CIK 0001056835 · 10% owner

WYNNEFIELD CAPITAL INC · CIK 0001251567 · 10% owner

Wynnefield Capital, Inc. Profit Sharing Plan · CIK 0001289453 · 10% owner

OBUS NELSON · CIK 0001017043 · 10% owner

LANDES JOSHUA · CIK 0001251568 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · See Footnotes

Disclosed balance after: 2,607,433

F2 · ownership.nature: The Reporting Person has an indirect beneficial ownership interest in 1,344,585 shares of Common Stock, which are directly beneficially owned by Wynnefield Partners Small Cap Value, L.P., as members of a group under Section 13(d) of the Securities Exchange Act of 1934, as amended (the "Exchange Act"). Wynnefield Partners Small Cap Value, L.P., which maintains offices at the same address as the Reporting Person, is filing this statement jointly with the Reporting Person. Wynnefield Capital Management, LLC, as the sole general partner of Wynnefield Partners Small Cap Value, L.P., has an indirect beneficial ownership interest in the shares of Common Stock that Wynnefield Partners Small Cap Value L.P. directly beneficially owns.

F3 · ownership.nature: Nelson Obus and Joshua Landes, as co-managing members of Wynnefield Capital Management, LLC, have an indirect beneficial ownership interest in the shares of Common Stock that Wynnefield Partners Small Cap Value, L.P. directly beneficially owns. Does not include 162,543 shares of Common Stock issuable upon conversion of certain shares of Convertible Preferred Stock that are immediately convertible.

F4 · ownership.nature: The Reporting Person has an indirect beneficial ownership interest in 895,498 shares of Common Stock, which are directly beneficially owned by Wynnefield Small Cap Value Offshore Fund, Ltd., as members of a group under Section 13(d) of the Exchange Act. Wynnefield Small Cap Value Offshore Fund, Ltd., which maintains offices at the same address as the Reporting Person, is filing this statement jointly with the Reporting Person. Wynnefield Capital, Inc. as the sole investment manager of Wynnefield Small Cap Value Offshore Fund, Ltd., has an indirect beneficial ownership interest in the shares of Common Stock that Wynnefield Small Cap Value Offshore Fund, Ltd. directly beneficially owns.

F5 · ownership.nature: Nelson Obus and Joshua Landes, as principal executive officers of Wynnefield Capital, Inc., have an indirect beneficial ownership interest in the shares of Common Stock that Wynnefield Small Cap Value Offshore Fund, Ltd. directly beneficially owns. Does not include 101,589 shares of Common Stock issuable upon conversion of certain shares of Convertible Preferred Stock that are immediately convertible.

F6 · ownership.nature: The Reporting Person has an indirect beneficial ownership interest in 367,350 shares of Common Stock, which are directly beneficially owned by Wynnefield Capital, Inc. Profit Sharing Plan, as members of a group under Section 13(d) of the Exchange Act. Wynnefield Capital, Inc. Profit Sharing Plan, which maintains offices at the same address as the Reporting Person, is filing this Form jointly with the Reporting Person. Mr. Obus and Mr. Landes, as co-trustees, has the power to vote and dispose of Wynnefield Capital, Inc. Profit Sharing Plan's investments in securities and has an indirect beneficial ownership interest in the shares of Common Stock that Wynnefield Capital, Inc. Profit Sharing Plan directly beneficially owns.

SEC source: 0001104659-24-106795 · tm2425764-1_4seq1.xml · nonDerivative · entry 1

WYNNEFIELD PARTNERS SMALL CAP VALUE LP I · CIK 0001251565 · 10% owner

WYNNEFIELD PARTNERS SMALL CAP VALUE LP · CIK 0000899083 · 10% owner

WYNNEFIELD SMALL CAP VALUE OFFSHORE FUND LTD · CIK 0001030806 · 10% owner

WYNNEFIELD CAPITAL MANAGEMENT LLC · CIK 0001056835 · 10% owner

WYNNEFIELD CAPITAL INC · CIK 0001251567 · 10% owner

Wynnefield Capital, Inc. Profit Sharing Plan · CIK 0001289453 · 10% owner

OBUS NELSON · CIK 0001017043 · 10% owner

LANDES JOSHUA · CIK 0001251568 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 2,095,783

F1 · ownership.direct: The Reporting Person directly beneficially owns 2,095,783 shares of common stock, $0.001 par value per share ("Common Stock") of Lifecore Biomedical, Inc. Wynnefield Capital Management, LLC, as the sole general partner of the Reporting Person, has an indirect beneficial ownership interest in the shares of Common Stock that the Reporting Person directly beneficially owns. Nelson Obus and Joshua Landes, as co-managing members of Wynnefield Capital Management, LLC, have an indirect beneficial ownership interest in the shares of Common Stock that the Reporting Person directly beneficially owns. Does not include 243,814 shares of Common Stock issuable upon conversion of certain shares of Series A Convertible Preferred Stock, par value $0.001 per share (the "Convertible Preferred Stock") that are immediately convertible.

SEC source: 0000921895-24-002254 · form409050032_10072024.xml · nonDerivative · entry 2

Kiper Christopher S · CIK 0001432744 · Director · 10% owner

Legion Partners Asset Management, LLC · CIK 0001560207 · Director · 10% owner

Legion Partners, L.P. I · CIK 0001595909 · Director · 10% owner

Legion Partners, L.P. II · CIK 0001618783 · Director · 10% owner

Legion Partners, LLC · CIK 0001682390 · Director · 10% owner

Legion Partners Holdings, LLC · CIK 0001682389 · Director · 10% owner

White Raymond T. · CIK 0001682494 · Director · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · By: Legion Partners, L.P. II

Disclosed balance after: 319,286

F1 · security: This Form 4 is filed jointly by Legion Partners, L.P. I ("Legion Partners I"), Legion Partners, L.P. II ("Legion Partners II"), Legion Partners, LLC ("General Partner"), Legion Partners Asset Management, LLC ("Legion Partners Asset Management"), Legion Partners Holdings, LLC ("Legion Partners Holdings"), Christopher S. Kiper and Raymond White (collectively, the "Reporting Persons"). Each of the Reporting Persons may be deemed to be a member of a Section 13(d) group that owns more than 10% of Lifecore Biomedical, Inc.'s (the "Issuer") outstanding shares of Common Stock. Each Reporting Person disclaims beneficial ownership of the securities reported herein except to the extent of his or its pecuniary interest therein, and this report shall not be deemed to be an admission that any Reporting Person is the beneficial owner of such securities for purposes of Section 16 or for any other purpose.

F2 · shares: Pursuant to a securities purchase agreement between the Issuer, Legion Partners I, Legion Partners II and certain other unaffiliated investors (collectively, the "Purchasers"), the Issuer agreed to issue and sell to the Purchasers shares of Common Stock at a price of $4.10 per share.

F7 · ownership.nature: Securities owned directly by Legion Partners II. General Partner is the general partner of Legion Partners II, Legion Partners Asset Management is the investment advisor of Legion Partners II, Legion Partners Holdings is the sole member of Legion Partners Asset Management and managing member of General Partner, and each of Messrs. Kiper and White are managing directors of Legion Partners Asset Management and managing members of Legion Partners Holdings. As a result of these relationships, General Partner, Legion Partners Asset Management, Legion Partners Holdings and Messrs. Kiper and White may be deemed to beneficially own the securities owned directly by Legion Partners II.

SEC source: 0000921895-24-002254 · form409050032_10072024.xml · nonDerivative · entry 1

Kiper Christopher S · CIK 0001432744 · Director · 10% owner

Legion Partners Asset Management, LLC · CIK 0001560207 · Director · 10% owner

Legion Partners, L.P. I · CIK 0001595909 · Director · 10% owner

Legion Partners, L.P. II · CIK 0001618783 · Director · 10% owner

Legion Partners, LLC · CIK 0001682390 · Director · 10% owner

Legion Partners Holdings, LLC · CIK 0001682389 · Director · 10% owner

White Raymond T. · CIK 0001682494 · Director · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · By: Legion Partners, L.P. I

Disclosed balance after: 4,084,268

F1 · security: This Form 4 is filed jointly by Legion Partners, L.P. I ("Legion Partners I"), Legion Partners, L.P. II ("Legion Partners II"), Legion Partners, LLC ("General Partner"), Legion Partners Asset Management, LLC ("Legion Partners Asset Management"), Legion Partners Holdings, LLC ("Legion Partners Holdings"), Christopher S. Kiper and Raymond White (collectively, the "Reporting Persons"). Each of the Reporting Persons may be deemed to be a member of a Section 13(d) group that owns more than 10% of Lifecore Biomedical, Inc.'s (the "Issuer") outstanding shares of Common Stock. Each Reporting Person disclaims beneficial ownership of the securities reported herein except to the extent of his or its pecuniary interest therein, and this report shall not be deemed to be an admission that any Reporting Person is the beneficial owner of such securities for purposes of Section 16 or for any other purpose.

F2 · shares: Pursuant to a securities purchase agreement between the Issuer, Legion Partners I, Legion Partners II and certain other unaffiliated investors (collectively, the "Purchasers"), the Issuer agreed to issue and sell to the Purchasers shares of Common Stock at a price of $4.10 per share.

F6 · ownership.nature: Securities owned directly by Legion Partners I. General Partner is the general partner of Legion Partners I, Legion Partners Asset Management is the investment advisor of Legion Partners I, Legion Partners Holdings is the sole member of Legion Partners Asset Management and managing member of General Partner, and each of Messrs. Kiper and White are managing directors of Legion Partners Asset Management and managing members of Legion Partners Holdings. As a result of these relationships, General Partner, Legion Partners Asset Management, Legion Partners Holdings and Messrs. Kiper and White may be deemed to beneficially own the securities owned directly by Legion Partners I.

SEC source: 0001628280-24-039547 · wk-form4_1725567522.xml · derivative · entry 2

Lake Ryan David · CIK 0001450325 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 750,000 shares

Expires 2029-09-03

F2 · derivative.exercise_price: Each performance-based restricted stock unit represents a contingent right to receive one share of the Issuer's common stock.

F3 · shares: Represents the maximum number of performance-based restricted stock units that can vest based on the Issuer's achievement of certain stock price milestones.

F4 · derivative.exercise_date: The performance-based restricted stock units vest, if at all, based on the Issuer's achievement of certain stock prices.

F3 · derivative.underlying_shares: Represents the maximum number of performance-based restricted stock units that can vest based on the Issuer's achievement of certain stock price milestones.

SEC source: 0001628280-24-039547 · wk-form4_1725567522.xml · nonDerivative · entry 1

Lake Ryan David · CIK 0001450325 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 262,500

F1 · price: The restricted stock units convert into common stock of Lifecore Biomedical, Inc. on a 1 for 1 basis.

SEC source: 0001628280-24-038091 · wk-form4_1724284516.xml · nonDerivative · entry 1

Antunes Humberto Calheiros · CIK 0001800145 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 24,554

F1 · price: The restricted stock units convert into common stock of Lifecore Biomedical, Inc. on a 1 for 1 basis.

F2 · price: Vests on earlier of July 8, 2025 or the date of the annual meeting of stockholders of the Company first held in calendar year 2025 (provided such date is no less than 50 weeks from July 8, 2024).

SEC source: 0001628280-24-038090 · wk-form4_1724284438.xml · nonDerivative · entry 1

Aryeh Jason · CIK 0001376960 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 24,554

F1 · price: The restricted stock units convert into common stock of Lifecore Biomedical, Inc. on a 1 for 1 basis.

F2 · price: Vests on earlier of July 8, 2025 or the date of the annual meeting of stockholders of the Company first held in calendar year 2025 (provided such date is no less than 50 weeks from July 8, 2024).

SEC source: 0001628280-24-038088 · wk-form4_1724284348.xml · nonDerivative · entry 1

Korenberg Matthew E · CIK 0001649903 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 24,554

F1 · price: The restricted stock units convert into common stock of Lifecore Biomedical, Inc. on a 1 for 1 basis.

F2 · price: Vests on earlier of July 8, 2025 or the date of the annual meeting of stockholders of the Company first held in calendar year 2025 (provided such date is no less than 50 weeks from July 8, 2024).

SEC source: 0001628280-24-038196 · wk-form4_1724353252.xml · nonDerivative · entry 1

Johnson Paul Harold · CIK 0002034858 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 24,554

F1 · price: The restricted stock units convert into common stock of Lifecore Biomedical, Inc. on a 1 for 1 basis.

F2 · price: Vests on earlier of July 8, 2025 or the date of the annual meeting of stockholders of the Company first held in calendar year 2025 (provided such date is no less than 50 weeks from July 8, 2024).

SEC source: 0001628280-24-040456 · wk-form4a_1726514653.xml · nonDerivative · entry 1

Antunes Humberto Calheiros · CIK 0001800145 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 27,554

F1 · price: The restricted stock units convert into common stock of Lifecore Biomedical, Inc. on a 1 for 1 basis.

F2 · price: Vests on earlier of July 8, 2025 or the date of the annual meeting of stockholders of the Company first held in calendar year 2025 (provided such date is no less than 50 weeks from July 8, 2024).

F3 · balance_after: Amendment includes 3,000 shares that were inadvertently omitted from the Form 3 filed on behalf of the reporting person on August 21, 2024.

SEC source: 0001628280-24-031636 · wk-form4_1720655620.xml · nonDerivative · entry 1

Barbarosh Craig A. · CIK 0001472457 · Director

10b5-1 filing: No plan indicated

Ownership: Indirect · In Trust

Disclosed balance after: 88,073

F1 · price: The restricted stock units convert into common stock of Lifecore Biomedical, Inc. on a 1 for 1 basis.

F2 · price: Vests on earlier of the first anniversary of the grant date or the date of the annual meeting of stockholders first held in calendar year 2025, subject to potential acceleration.

SEC source: 0001628280-24-031632 · wk-form4_1720655363.xml · nonDerivative · entry 1

Diradoorian Raymond H · CIK 0001352121 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 69,978

F1 · price: The restricted stock units convert into common stock of Lifecore Biomedical, Inc. on a 1 for 1 basis.

F2 · price: Vests on earlier of the first anniversary of the grant date or the date of the annual meeting of stockholders first held in calendar year 2025, subject to potential acceleration.

SEC source: 0001628280-24-031634 · wk-form4_1720655516.xml · nonDerivative · entry 1

Calloway Nathaniel · CIK 0001952771 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 58,069

F1 · price: The restricted stock units convert into common stock of Lifecore Biomedical, Inc. on a 1 for 1 basis.

F2 · price: Vests on earlier of the first anniversary of the grant date or the date of the annual meeting of stockholders first held in calendar year 2025, subject to potential acceleration.

SEC source: 0001628280-24-031630 · wk-form4_1720655169.xml · nonDerivative · entry 1

EDWARDS JEFFREY L · CIK 0001190642 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 79,667

F1 · price: The restricted stock units convert into common stock of Lifecore Biomedical, Inc. on a 1 for 1 basis.

F2 · price: Vests on earlier of the first anniversary of the grant date or the date of the annual meeting of stockholders first held in calendar year 2025, subject to potential acceleration.

SEC source: 0001628280-24-031628 · wk-form4_1720655057.xml · nonDerivative · entry 1

HOUDE LOVAS KATRINA · CIK 0001269294 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 89,906

F1 · price: The restricted stock units convert into common stock of Lifecore Biomedical, Inc. on a 1 for 1 basis.

F2 · price: Vests on earlier of the first anniversary of the grant date or the date of the annual meeting of stockholders first held in calendar year 2025, subject to potential acceleration.

SEC source: 0001628280-24-031626 · wk-form4_1720654981.xml · nonDerivative · entry 1

OBUS NELSON · CIK 0001017043 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 118,687

F1 · price: The restricted stock units convert into common stock of Lifecore Biomedical, Inc. on a 1 for 1 basis.

F2 · price: Vests on earlier of the first anniversary of the grant date or the date of the annual meeting of stockholders first held in calendar year 2025, subject to potential acceleration.

SEC source: 0001628280-24-031624 · wk-form4_1720654875.xml · nonDerivative · entry 1

Schechter Joshua · CIK 0001336601 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 87,667

F1 · price: The restricted stock units convert into common stock of Lifecore Biomedical, Inc. on a 1 for 1 basis.

F2 · price: Vests on earlier of the first anniversary of the grant date or the date of the annual meeting of stockholders first held in calendar year 2025, subject to potential acceleration.

SEC source: 0000921895-24-001545 · form409050032_07102024.xml · nonDerivative · entry 1

Kiper Christopher S · CIK 0001432744 · Director

Legion Partners Asset Management, LLC · CIK 0001560207 · Director

Legion Partners, L.P. I · CIK 0001595909 · Director

Legion Partners, L.P. II · CIK 0001618783 · Director

Legion Partners, LLC · CIK 0001682390 · Director

Legion Partners Holdings, LLC · CIK 0001682389 · Director

White Raymond T. · CIK 0001682494 · Director

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 58,069

F1 · security: This Form 4 is filed jointly by Legion Partners, L.P. I, Legion Partners, L.P. II, Legion Partners, LLC, Legion Partners Asset Management, LLC ("Legion Partners Asset Management"), Legion Partners Holdings, LLC, Christopher S. Kiper and Raymond White (collectively, the "Reporting Persons"). Each Reporting Person disclaims beneficial ownership of the securities reported herein except to the extent of his or its pecuniary interest therein, and this report shall not be deemed to be an admission that any Reporting Person is the beneficial owner of such securities for purposes of Section 16 or for any other purpose.

F4 · kind: Mr. Kiper serves on the Board of the Issuer as a representative of Legion Partners Asset Management and its affiliates. Mr. Kiper does not have a right to any economic interest in securities of the Issuer granted to him by the Issuer in respect of his Board position, except to the extent of his role as a Managing Director of Legion Partners Asset Management. Legion Partners Asset Management is entitled to receive all of the economic interest in securities granted to Mr. Kiper by the Issuer in respect of Mr. Kiper's Board position. Mr. Kiper disclaims beneficial ownership of the Issuer's securities to which this report relates and at no time has Mr. Kiper had any economic interest in such securities except any indirect economic interest through Legion Partners Asset Management and its affiliates, entities in which Mr. Kiper has a controlling interest and investment control.

F5 · kind: The securities held by Mr. Kiper as described in footnote (4), including the 30,000 restricted stock units described herein, are securities in which Legion Partners Asset Management has all of the direct economic interest. Legion Partners Holdings is the sole member of Legion Partners Asset Management and each of Messrs. Kiper and White are Managing Directors of Legion Partners Asset Management. As a result of these relationships, Legion Partners Holdings and Messrs. Kiper and White may be deemed to beneficially own the securities owned directly by Legion Partners Asset Management.

F2 · shares: The restricted stock units convert into common stock of Lifecore Biomedical, Inc. (the "Issuer") on a 1 for 1 basis.

F3 · shares: The restricted stock units will vest and be settled on the earlier of the 1st anniversary of the grant date or the date of the 2025 Annual Meeting of Stockholders (provided such date is no less than 50 weeks from grant date).

F2 · price: The restricted stock units convert into common stock of Lifecore Biomedical, Inc. (the "Issuer") on a 1 for 1 basis.

F3 · price: The restricted stock units will vest and be settled on the earlier of the 1st anniversary of the grant date or the date of the 2025 Annual Meeting of Stockholders (provided such date is no less than 50 weeks from grant date).

F4 · balance_after: Mr. Kiper serves on the Board of the Issuer as a representative of Legion Partners Asset Management and its affiliates. Mr. Kiper does not have a right to any economic interest in securities of the Issuer granted to him by the Issuer in respect of his Board position, except to the extent of his role as a Managing Director of Legion Partners Asset Management. Legion Partners Asset Management is entitled to receive all of the economic interest in securities granted to Mr. Kiper by the Issuer in respect of Mr. Kiper's Board position. Mr. Kiper disclaims beneficial ownership of the Issuer's securities to which this report relates and at no time has Mr. Kiper had any economic interest in such securities except any indirect economic interest through Legion Partners Asset Management and its affiliates, entities in which Mr. Kiper has a controlling interest and investment control.

F5 · balance_after: The securities held by Mr. Kiper as described in footnote (4), including the 30,000 restricted stock units described herein, are securities in which Legion Partners Asset Management has all of the direct economic interest. Legion Partners Holdings is the sole member of Legion Partners Asset Management and each of Messrs. Kiper and White are Managing Directors of Legion Partners Asset Management. As a result of these relationships, Legion Partners Holdings and Messrs. Kiper and White may be deemed to beneficially own the securities owned directly by Legion Partners Asset Management.

F4 · ownership.direct: Mr. Kiper serves on the Board of the Issuer as a representative of Legion Partners Asset Management and its affiliates. Mr. Kiper does not have a right to any economic interest in securities of the Issuer granted to him by the Issuer in respect of his Board position, except to the extent of his role as a Managing Director of Legion Partners Asset Management. Legion Partners Asset Management is entitled to receive all of the economic interest in securities granted to Mr. Kiper by the Issuer in respect of Mr. Kiper's Board position. Mr. Kiper disclaims beneficial ownership of the Issuer's securities to which this report relates and at no time has Mr. Kiper had any economic interest in such securities except any indirect economic interest through Legion Partners Asset Management and its affiliates, entities in which Mr. Kiper has a controlling interest and investment control.

F5 · ownership.direct: The securities held by Mr. Kiper as described in footnote (4), including the 30,000 restricted stock units described herein, are securities in which Legion Partners Asset Management has all of the direct economic interest. Legion Partners Holdings is the sole member of Legion Partners Asset Management and each of Messrs. Kiper and White are Managing Directors of Legion Partners Asset Management. As a result of these relationships, Legion Partners Holdings and Messrs. Kiper and White may be deemed to beneficially own the securities owned directly by Legion Partners Asset Management.

SEC source: 0001628280-24-024782 · wk-form4_1716414520.xml · derivative · entry 3

Josephs Paul · CIK 0002022547 · Director · Chief Executive Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 1,500,000 shares

Expires 2029-05-20

F2 · derivative.exercise_price: Each performance-based restricted stock unit represents a contingent right to receive one share of the Issuer's common stock.

F3 · shares: Represents the maximum number of performance-based restricted stock units that can vest based on the Issuer's achievement of certain stock price milestones.

F4 · derivative.exercise_date: The performance-based restricted stock units vest, if it all, based on the Issuer's achievement of certain stock prices.

F3 · derivative.underlying_shares: Represents the maximum number of performance-based restricted stock units that can vest based on the Issuer's achievement of certain stock price milestones.

SEC source: 0001628280-24-024782 · wk-form4_1716414520.xml · nonDerivative · entry 2

Josephs Paul · CIK 0002022547 · Director · Chief Executive Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 516,025

F1 · price: The restricted stock units convert into common stock of Lifecore Biomedical, Inc. on a 1 for 1 basis.

SEC source: 0001628280-24-024782 · wk-form4_1716414520.xml · nonDerivative · entry 1

Josephs Paul · CIK 0002022547 · Director · Chief Executive Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 525,000

F1 · price: The restricted stock units convert into common stock of Lifecore Biomedical, Inc. on a 1 for 1 basis.

SEC source: 0001628280-24-003144 · wk-form4_1706918511.xml · derivative · entry 3

Schechter Joshua · CIK 0001336601 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 9,554 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: The restricted stock units convert into common stock of Lifecore Biomedical, Inc. on a 1 for 1 basis.

F2 · derivative.expiration_date: The restricted stock units vested on February 1, 2024.

SEC source: 0001628280-24-003144 · wk-form4_1706918511.xml · nonDerivative · entry 1

Schechter Joshua · CIK 0001336601 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 57,667

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: The restricted stock units convert into common stock of Lifecore Biomedical, Inc. on a 1 for 1 basis.

SEC source: 0001628280-24-003139 · wk-form4_1706917311.xml · derivative · entry 2

Calloway Nathaniel · CIK 0001952771 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 3,981 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: The restricted stock units convert into common stock of Lifecore Biomedical, Inc. on a 1 for 1 basis.

F2 · derivative.expiration_date: The restricted stock units vested on February 1, 2024.

SEC source: 0001628280-24-003139 · wk-form4_1706917311.xml · nonDerivative · entry 1

Calloway Nathaniel · CIK 0001952771 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 28,069

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: The restricted stock units convert into common stock of Lifecore Biomedical, Inc. on a 1 for 1 basis.

SEC source: 0001628280-24-003137 · wk-form4_1706917221.xml · derivative · entry 2

OBUS NELSON · CIK 0001017043 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 9,554 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: The restricted stock units convert into common stock of Lifecore Biomedical, Inc. on a 1 for 1 basis.

F2 · derivative.expiration_date: The restricted stock units vested on February 1, 2024.

SEC source: 0001628280-24-003137 · wk-form4_1706917221.xml · nonDerivative · entry 1

OBUS NELSON · CIK 0001017043 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 88,687

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: The restricted stock units convert into common stock of Lifecore Biomedical, Inc. on a 1 for 1 basis.

SEC source: 0001628280-24-003134 · wk-form4_1706916917.xml · derivative · entry 2

EDWARDS JEFFREY L · CIK 0001190642 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 9,554 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: The restricted stock units convert into common stock of Lifecore Biomedical, Inc. on a 1 for 1 basis.

F2 · derivative.expiration_date: The restricted stock units vested on February 1, 2024.

SEC source: 0001628280-24-003134 · wk-form4_1706916917.xml · nonDerivative · entry 1

EDWARDS JEFFREY L · CIK 0001190642 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 49,667

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: The restricted stock units convert into common stock of Lifecore Biomedical, Inc. on a 1 for 1 basis.

SEC source: 0001628280-24-003132 · wk-form4_1706916810.xml · derivative · entry 2

Diradoorian Raymond H · CIK 0001352121 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 9,554 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: The restricted stock units convert into common stock of Lifecore Biomedical, Inc. on a 1 for 1 basis.

F2 · derivative.expiration_date: The restricted stock units vested on February 1, 2024.

SEC source: 0001628280-24-003132 · wk-form4_1706916810.xml · nonDerivative · entry 1

Diradoorian Raymond H · CIK 0001352121 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 39,978

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: The restricted stock units convert into common stock of Lifecore Biomedical, Inc. on a 1 for 1 basis.

SEC source: 0001628280-24-003128 · wk-form4_1706916694.xml · derivative · entry 2

HOUDE LOVAS KATRINA · CIK 0001269294 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 9,554 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: The restricted stock units convert into common stock of Lifecore Biomedical, Inc. on a 1 for 1 basis.

F2 · derivative.expiration_date: The restricted stock units vested on February 1, 2024.

SEC source: 0001628280-24-003128 · wk-form4_1706916694.xml · nonDerivative · entry 1

HOUDE LOVAS KATRINA · CIK 0001269294 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 59,906

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: The restricted stock units convert into common stock of Lifecore Biomedical, Inc. on a 1 for 1 basis.

SEC source: 0001628280-24-003126 · wk-form4_1706916605.xml · derivative · entry 2

Barbarosh Craig A. · CIK 0001472457 · Director

10b5-1 filing: No plan indicated

Ownership: Indirect · In Trust

Disclosed balance after: 0

Underlying: Common Stock · 9,554 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: The restricted Stock units convert into common stock of Lifecore Biomedical, Inc. on a 1 for 1 basis.

F2 · derivative.expiration_date: The restricted stock units vested on February 1, 2024.

SEC source: 0001628280-24-003126 · wk-form4_1706916605.xml · nonDerivative · entry 1

Barbarosh Craig A. · CIK 0001472457 · Director

10b5-1 filing: No plan indicated

Ownership: Indirect · In Trust

Disclosed balance after: 58,073

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: The restricted Stock units convert into common stock of Lifecore Biomedical, Inc. on a 1 for 1 basis.

SEC source: 0001628280-24-001842 · wk-form4_1705951591.xml · derivative · entry 3

Morberg John D · CIK 0001345964 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 17,500 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: The restricted stock units convert into common stock of Lifecore Biomedical, Inc. on a 1 for 1 basis.

F2 · derivative.expiration_date: The restricted stock units vested on January 18, 2024.

SEC source: 0001628280-24-001842 · wk-form4_1705951591.xml · nonDerivative · entry 2

Morberg John D · CIK 0001345964 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 125,617

F1 · price: The restricted stock units convert into common stock of Lifecore Biomedical, Inc. on a 1 for 1 basis.

SEC source: 0001628280-24-001842 · wk-form4_1705951591.xml · nonDerivative · entry 1

Morberg John D · CIK 0001345964 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 131,900

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: The restricted stock units convert into common stock of Lifecore Biomedical, Inc. on a 1 for 1 basis.

SEC source: 0001628280-24-001074 · wk-form4_1704932063.xml · derivative · entry 2

Calloway Nathaniel · CIK 0001952771 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 5,906 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: The restricted stock units convert into common stock of Lifecore Biomedical, Inc. on a 1 for 1 basis.

F2 · derivative.expiration_date: The restricted stock units vested on January 9, 2024.

SEC source: 0001628280-24-001074 · wk-form4_1704932063.xml · nonDerivative · entry 1

Calloway Nathaniel · CIK 0001952771 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 24,088

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: The restricted stock units convert into common stock of Lifecore Biomedical, Inc. on a 1 for 1 basis.

SEC source: 0000921895-23-001426 · form409050032_06052023.xml · nonDerivative · entry 1

Kiper Christopher S · CIK 0001432744 · Director

Legion Partners Asset Management, LLC · CIK 0001560207 · Director

Legion Partners, L.P. I · CIK 0001595909 · Director

Legion Partners, L.P. II · CIK 0001618783 · Director

Legion Partners, LLC · CIK 0001682390 · Director

Legion Partners Holdings, LLC · CIK 0001682389 · Director

White Raymond T. · CIK 0001682494 · Director

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 28,069

F1 · security: This Form 4 is filed jointly by Legion Partners, L.P. I, Legion Partners, L.P. II, Legion Partners, LLC, Legion Partners Asset Management, LLC ("Legion Partners Asset Management"), Legion Partners Holdings, LLC, Christopher S. Kiper and Raymond White (collectively, the "Reporting Persons"). Each Reporting Person disclaims beneficial ownership of the securities reported herein except to the extent of his or its pecuniary interest therein, and this report shall not be deemed to be an admission that any Reporting Person is the beneficial owner of such securities for purposes of Section 16 or for any other purpose.

F4 · kind: Mr. Kiper serves on the Board of the Issuer as a representative of Legion Partners Asset Management and its affiliates. Mr. Kiper does not have a right to any economic interest in securities of the Issuer granted to him by the Issuer in respect of his Board position, except to the extent of his role as a Managing Director of Legion Partners Asset Management. Legion Partners Asset Management is entitled to receive all of the economic interest in securities granted to Mr. Kiper by the Issuer in respect of Mr. Kiper's Board position. Mr. Kiper disclaims beneficial ownership of the Issuer's securities to which this report relates and at no time has Mr. Kiper had any economic interest in such securities except any indirect economic interest through Legion Partners Asset Management and its affiliates, entities in which Mr. Kiper has a controlling interest and investment control.

F4 · shares: Mr. Kiper serves on the Board of the Issuer as a representative of Legion Partners Asset Management and its affiliates. Mr. Kiper does not have a right to any economic interest in securities of the Issuer granted to him by the Issuer in respect of his Board position, except to the extent of his role as a Managing Director of Legion Partners Asset Management. Legion Partners Asset Management is entitled to receive all of the economic interest in securities granted to Mr. Kiper by the Issuer in respect of Mr. Kiper's Board position. Mr. Kiper disclaims beneficial ownership of the Issuer's securities to which this report relates and at no time has Mr. Kiper had any economic interest in such securities except any indirect economic interest through Legion Partners Asset Management and its affiliates, entities in which Mr. Kiper has a controlling interest and investment control.

F2 · price: The restricted stock units convert into common stock of Lifecore Biomedical, Inc. (the "Issuer") on a 1 for 1 basis.

F3 · price: The restricted stock units will vest and be settled on the earlier of the 1st anniversary of the grant date or the date of the 2024 Annual Meeting of Stockholders (provided such date is no less than 50 weeks from grant date).

F4 · balance_after: Mr. Kiper serves on the Board of the Issuer as a representative of Legion Partners Asset Management and its affiliates. Mr. Kiper does not have a right to any economic interest in securities of the Issuer granted to him by the Issuer in respect of his Board position, except to the extent of his role as a Managing Director of Legion Partners Asset Management. Legion Partners Asset Management is entitled to receive all of the economic interest in securities granted to Mr. Kiper by the Issuer in respect of Mr. Kiper's Board position. Mr. Kiper disclaims beneficial ownership of the Issuer's securities to which this report relates and at no time has Mr. Kiper had any economic interest in such securities except any indirect economic interest through Legion Partners Asset Management and its affiliates, entities in which Mr. Kiper has a controlling interest and investment control.

F4 · ownership.direct: Mr. Kiper serves on the Board of the Issuer as a representative of Legion Partners Asset Management and its affiliates. Mr. Kiper does not have a right to any economic interest in securities of the Issuer granted to him by the Issuer in respect of his Board position, except to the extent of his role as a Managing Director of Legion Partners Asset Management. Legion Partners Asset Management is entitled to receive all of the economic interest in securities granted to Mr. Kiper by the Issuer in respect of Mr. Kiper's Board position. Mr. Kiper disclaims beneficial ownership of the Issuer's securities to which this report relates and at no time has Mr. Kiper had any economic interest in such securities except any indirect economic interest through Legion Partners Asset Management and its affiliates, entities in which Mr. Kiper has a controlling interest and investment control.

F5 · ownership.direct: The securities described in footnotes (2) and (3) represent securities in which Legion Partners Asset Management has all of the direct economic interest. Legion Partners Holdings is the sole member of Legion Partners Asset Management and each of Messrs. Kiper and White are Managing Directors of Legion Partners Asset Management. As a result of these relationships, Legion Partners Holdings and Messrs. Kiper and White may be deemed to beneficially own the securities owned directly by Legion Partners Asset Management.

SEC source: 0001628280-23-020846 · wk-form4_1685993517.xml · nonDerivative · entry 1

Barbarosh Craig A. · CIK 0001472457 · Director

10b5-1 filing: No plan indicated

Ownership: Indirect · In Trust

Disclosed balance after: 48,519

F1 · price: The restricted stock units convert into common stock of Lifecore Biomedical, Inc. on a 1 for 1 basis.

F2 · price: Restricted Stock Units will vest and be settled on the earlier of the 1st anniversary of the grant date or the date of the 2024 Annual Meeting of Stockholders (provided such date is no less than 50 weeks from Grant Date).

SEC source: 0001628280-23-020843 · wk-form4_1685993416.xml · nonDerivative · entry 1

Diradoorian Raymond H · CIK 0001352121 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 30,424

F1 · price: The restricted stock units convert into common stock of Lifecore Biomedical, Inc. on a 1 for 1 basis.

F2 · price: Restricted Stock Units will vest and be settled on the earlier of the 1st anniversary of the grant date or the date of the 2024 Annual Meeting of Stockholders (provided such date is no less than 50 weeks from Grant Date).

SEC source: 0001628280-23-020841 · wk-form4_1685993261.xml · nonDerivative · entry 2

Hall James G · CIK 0001368626 · Director · Chief Executive Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 276,096

F1 · price: The restricted stock units convert into common stock of Lifecore Biomedical, Inc. on a 1 for 1 basis.

F3 · price: Restricted Stock Units will vest on the 3rd anniversary of the grant date or if earlier, upon a Change in Control.

SEC source: 0001628280-23-020841 · wk-form4_1685993261.xml · nonDerivative · entry 1

Hall James G · CIK 0001368626 · Director · Chief Executive Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 201,096

F1 · price: The restricted stock units convert into common stock of Lifecore Biomedical, Inc. on a 1 for 1 basis.

F2 · price: Restricted Stock Units will vest on the 3rd anniversary of the grant date.

SEC source: 0001628280-23-020839 · wk-form4_1685993042.xml · nonDerivative · entry 2

Morberg John D · CIK 0001345964 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 114,400

F1 · price: The restricted stock units convert into common stock of Lifecore Biomedical, Inc. on a 1 for 1 basis.

F3 · price: Restricted Stock Units will vest on the 3rd anniversary of the grant date or if earlier, upon a Change in Control.

SEC source: 0001628280-23-020839 · wk-form4_1685993042.xml · nonDerivative · entry 1

Morberg John D · CIK 0001345964 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 64,400

F1 · price: The restricted stock units convert into common stock of Lifecore Biomedical, Inc. on a 1 for 1 basis.

F2 · price: Restricted Stock Units will vest on the 3rd anniversary of the grant date.

SEC source: 0001628280-23-020835 · wk-form4_1685992772.xml · nonDerivative · entry 1

Calloway Nathaniel · CIK 0001952771 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 18,182

F1 · price: The restricted stock units convert into common stock of Lifecore Biomedical, Inc. on a 1 for 1 basis.

F2 · price: Restricted Stock Units will vest and be settled on the earlier of the 1st anniversary of the grant date or the date of the 2024 Annual Meeting of Stockholders (provided such date is no less than 50 weeks from Grant Date).